Basic Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Dec 14, 2019; 25(46): 6713-6727
Published online Dec 14, 2019. doi: 10.3748/wjg.v25.i46.6713
Table 1 Relationship between expression levels of SPARC mRNA and clinicopathological characteristics, n (%)
ParametersTotal, n = 66Expression level of SPARC gene
P value
Low, n = 42High, n = 24
Age in yr
< 602116 (76.2)5 (23.8)0.186
≥ 604526 (57.8)19 (42.2)
Gender
Male5132 (62.7)19 (37.3)0.348
Female1510 (66.7)5 (33.3)
Size in cm
< 52718 (66.7)9 (33.3)0.372
≥ 53924 (61.5)15 (38.4)
Differentiation
Good/moderate168 (50.0)8 (50.0)0.154
Poor5034 (68.0)16 (32.0)
Location
Upper83 (37.5)5 (62.5)0.759
Middle188 (44.4)10 (56.6)
Lower4031 (77.5)9 (22.5)
Macroscopic type
Borrmann I + II196 (31.6)13 (68.4)0.015a
Borrmann III + IV4736 (76.6)11 (23.4)
TNM stage
I + II277 (25.9)20 (74.1)0.001a
III + IV3935 (89.8)4 (10.2)
Lymph node metastasis
-186 (33.3)12 (66.7)0.001a
+4836 (75.0)12 (25.0)
Table 2 Relationship between methylation status of SPARC gene and clinicopathological characteristics, n (%)
ParametersTotal, n = 66Methylation status of SPARC
P value
U, n = 19P, n = 11M, n = 36
Age in yr
< 60216 (28.6)1 (4.8)14 (66.7)0.178
≥ 604513 (28.9)10 (22.2)22 (48.9)
Gender
Male5117 (33.3)8 (15.7)26 (51.0)0.323
Female152 (13.3)3 (20.0)10 (66.7)
Size in cm
< 5276 (22.2)6 (22.2)15 (55.6)0.463
≥ 53913 (33.3)5 (12.8)21 (53.8)
Differentiation
Good/moderate166 (37.5)4 (25.0)6 (37.5)0.278
Poor5013 (26.0)7 (14.0)30 (60.0)
Location
Upper82 (25.0)3 (37.5)3 (37.5)0.297
Middle186 (33.3)4 (22.2)8 (44.4)
Lower4011 (27.5)4 (10.0)25 (62.5)
Macroscopic type
Borrmann I + II199 (47.4)6 (31.6)4 (21.1)0.002a
Borrmann III + IV4710 (21.3)5 (10.6)32 (68.1)
TNM stage
I + II2714 (51.9)8 (29.6)5 (18.5)0.001a
III + IV395 (12.8)3 (7.7)31 (79.5)
Lymph node metastasis
-1813 (72.2)2 (11.1)3 (16.7)0.001a
+486 (12.5)9 (18.8)33 (68.8)